webinar register page

New Alternative and Approach Methods to Assess Genotoxicity in Human Relevant Systems
We are showcasing our new Chief Scientific Officer, Leslie Recio, PhD, DABT ,who will discuss integrating traditional genetic toxicology endpoints with genomic profiling to assess genotoxicity in the HepaRG™ cell platform. High throughput comet assay using CometChip® technology, a single cell array platform developed at MIT, flow cytometry-based micronucleus (MN) assay, and toxicogenomics can be integrated into a single experiment for uses as a human-relevant in vitro alternative to rodent genotoxicity assessments.

What you'll learn: 

Metabolically competent HepaRG™ cells can be used to quantify traditional measures of genotoxicity: the comet assay using high throughput CometChip® technology and flow cytometry-based micronucleus assay.

Toxicogenomics profiling in HepaRG™ cells can be used to assess Mode-of-Action.

The HepaRG™ genotoxicity testing platform can be integrated with measures of genotoxicity to derive BMD and at ScitoVation IVIVE to provide quantitative measures of potential risk to humans.


Webinar logo
* Required information